Idarrubicina Azevedos

Idarubicin, the active ingredient in Idarrubicina Azevedos, is an anthracycline antibiotic presented as an injectable solution for intravenous use. It is used to treat acute myeloid leukemia and other acute leukemias in adult patients.

GNH USA supplies Idarrubicina Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Idarubicin is employed in the treatment of acute leukemic disorders, targeting rapidly proliferating malignant cells.

Acute Myeloid Leukemia (AML): induces remission by destroying leukemic blasts. Acute Lymphoblastic Leukemia (ALL): contributes to disease control in adult patients. Other acute leukemias: provides cytotoxic activity where standard regimens are indicated.

Idarubicin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Myelosuppression (low blood counts) - Mucositis (mouth sores) - Fatigue - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity (heart failure or reduced ejection fraction) - Severe infections due to neutropenia - Hemorrhage or bleeding complications - Secondary acute myeloid leukemia - Hepatic toxicity (elevated liver enzymes) - Pulmonary toxicity (interstitial pneumonitis)

Prior to initiating therapy, clinicians should assess baseline organ function and monitor for toxicity throughout treatment.

Monitor cardiac function: baseline and periodic echocardiograms due to risk of cardiotoxicity. Assess blood counts: regular CBC to detect myelosuppression. Evaluate liver function: monitor transaminases and bilirubin. Avoid concurrent anthracyclines: increased cumulative cardiac risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin can interact with several drug classes, requiring careful management to avoid additive toxicity.

Major Interactions (Avoid): - Concurrent use with other anthracyclines: additive cardiotoxicity. - Combination with trastuzumab: heightened risk of heart failure. - Co‑administration with strong CYP3A4 inhibitors: may raise plasma concentrations. - Concurrent chest radiotherapy: increased cardiac toxicity.

Moderate Interactions (Monitor Closely): - Use with other myelosuppressive agents: enhanced bone‑marrow suppression. - Concurrent anticoagulants or antiplatelet drugs: increased bleeding risk.